TABLE 2.

Adverse events reported in part A and part C of the study (safety population ^a )

PART A b
Adverse event, n (%) c	Placebo (N = 23)	GSK3358699
		1 mg (n = 5)	3 mg (n = 3)	10 mg (n = 6)	20 mg (n = 6)	25 mg (n = 12)	30 mg (n = 6)	40 mg (n = 6)
Any AE	4 (17)	2 (40)	3 (100)	2 (33)	3 (50)	8 (67)	4 (67)	3 (50)
Any nonserious treatment‐related AE	1 (4)	0	1 (33)	0	0	0	0	0
Diarrhoea	0	0	1 (33)	0	0	0	0	0
Nausea	0	0	1 (33)	0	0	0	0	0
Transaminase increased	1 (4)	0	0	0	0	0	0	0
AEs leading to withdrawal	0	1 (20)	0	1 (17)	0	0	0	0
Neutropenia	0	1 (20)	0	0	0	0	0	0
Ventricular tachycardia (nonsustained)	0	0	0	1 (17)	0	0	0	0

PART C d
Adverse event, n (%) c	Placebo (N = 11)	GSK3358699 10 mg QD (N = 14)
Any AE	7 (64)	7 (50)
Any nonserious treatment‐related AE	3 (27)	3 (21)
Tachycardia	1 (9)	1 (7)
Atrial fibrillation	1 (9)	0
Palpitations	1 (9)	0
Ventricular extrasystoles	0	1 (7)
Ventricular tachycardia (nonsustained)	0	1 (7)
Serious AE	0	1 (7)
Atrial fibrillation	0	1 (7)
AEs leading to withdrawal	1 (9)	3 (21)
Atrial fibrillation	0	1 (7)
Tachycardia	0	1 (7)
Ventricular tachycardia (nonsustained)	0	1 (7)
Keratitis	1 (9)	0

Abbreviation: AE, adverse event.

^a The safety population consisted of all randomized participants who received at least one dose of study treatment.

^b Part A was a single ascending‐dose crossover study in two interlocking cohorts. Each participant received a maximum of two single ascending oral doses of GSK3358699 (1, 3, 10, 20, 40 or 30 mg) and one dose of placebo.

^c The data presented represent the number of participants who experienced an adverse event.

^d In part C, participants received 10 mg of GSK3358699 or placebo daily for up to 14 days.